Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q5TCQ9

UPID:
MAGI3_HUMAN

ALTERNATIVE NAMES:
Membrane-associated guanylate kinase inverted 3

ALTERNATIVE UPACC:
Q5TCQ9; A0A024R0E9; A0A024R0H3; Q5TCQ8; Q5TCR0; Q9H2V6; Q9H5Y8; Q9HBC4; Q9HCD8

BACKGROUND:
The protein Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3, also known as MAGI3, serves as a critical scaffolding component at cellular junctions, regulating cell signaling and processes. By cooperating with PTEN, MAGI3 influences AKT1 kinase activity. Its association with PTPRB and tyrosine-phosphorylated proteins suggests a role in linking receptor tyrosine phosphatase to plasma membrane substrates. MAGI3 is involved in TGFA trafficking in polarized epithelial cells and modulates LPAR2's activation of ERK and RhoA pathways, as well as the JNK signaling cascade through interactions with FZD4 and VANGL2.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 offers a pathway to identifying novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.